OBJECTIVE: To study the in vitro anti-tumor activity of tungstophosphate compound(K6[P2W18O62]?14H2O) with Dawson structure.METHODS: MCF-7 cells were treated with different concentration of K6[P2W18O62]?14H2O,then its IC50 was measured by MTT assay;flow cytometry was applied to analyze cell cycle and apoptosis by computing the ratio of MCF-7 cells in different phase and its apoptotic ratio.Cell growth and viability were measured by trypan blue staining and cell counting by computing the ratio of living cells.The synergetic anti-tumor activity of tungstophosphate compound(K6[P2W18O62]?14H2O) and pharmorubicin was studied.RESULTS: K6[P2W18O62]?14H2O inhibited MCF-7 cell proliferation with IC50 of(33.7?3.2) ?mol?L-1,it reduced the proportions of MCF-7 cells at S phase and G1 phase,with the apoptotic rate at 3.7%～29.2% within 48 h.The percentage of living cells was 95.37%～76.78% at 48 h.As compared with pharmorubicin alone,the addition of K6[P2W18O62]?14H2O to pharmorubicin showed a significantly higher inhibitory action on proliferation of MCF-7 cells(P

Objective To investigate the effects of deguelin on the proliferation inhibition and apoptosis induction in RPMI-8226 cells in vitro,as well as the regulation of steroid receptor coactivator-3(SRC-3)to explore the relationship between them.Methods The effect of deguelin on the growth of RPMI-8226 cells was studied by MTT assay.Apoptosis was detected through Hoechst 33258 staining and Annexin-V FITC/PI double-labeled cytometry.RT-PCR Technology was applied to assessment of the mRNA expression of SRC-3,whereas,SRC-3 protein expression and localization were determined by using immunohistochemistry method.Results Deguelin presented striking proliferation inhibition potency on RPMI-8226 cells in vitro and apoptosis induction activity in a time-and dose-dependent manner.The IC50 value for 24 h was(54.55?0.40)nmol/L,(17.04?0.73)% RPMI-8226 cells went apoptotic when treated with 25 nmol/L deguelin for 24 h,with the dose of deguelin increasing to 100 nmol/L,(63.57?1.36)% cells were apoptotic.Over-expression of SRC-3 was found in RPMI-8226 cells,whereas the mRNA and protein expression levels of SRC-3 were significantly downregulated in RPMI-8226 cells induced by deguelin in a dose-dependent manner.The disposition of SRC-3 was situated mainly at the nuclear,occasionally in the cytoplasm.Conclusion Deguelin exhibited potent proliferation inhibition to the human myeloma cell line RPMI-8226 cells,furthermore,deguelin might induce RPMI-8226 cells apoptosis in a dose-dependent manner,which might correspond to the regulation of the expression of SRC-3.

Objective To analyze the quality of Cortex Moudan which grew for four years from main planting parts in Anhui province.Methods According to Pharmacopoeias of People Republic of China(2005 edition),the water content,the total ash content,ash content of acid infusibility,the content of the thing soak out and paeonol content were measured to investigate the quality of Cortex Moudan.Results Paeonol content of Cortex Moudan collected from main planting parts in Anhui province was from 0.98% to 1.77%.Conclusion The quality of Cortex Moudan from Nanling is the best of all.

Objective To investigate the expression of vascular endothelial growth factor (VEGF) and Bax in non‐small cell lung cancer (NSCLC) and clinical value .Methods Paraffin specimens were collected from 80 cases of NSCLC tissues(NSCLC group) and 20 cases of normal lung tissue adjacent to benign lesions(control group) .Western blot and immunohistochemistry were used to dectect the expression of VEGF and Bax .The relationship of the expression of VEGF and Bax with histological classifica‐tion ,stage ,lymph mode metastasis were analyzed .Results The expression of VEGF in NSCLC group was higher than that in con‐trol group ,the differences were statistically significant (P<0 .05) .The higher expression of VEGF in the group of stage Ⅲ‐Ⅳ was obtained than that in the group of stage Ⅰ‐Ⅱ (P<0 .05) .The higher expression of VEGF in the group with lymph mode metasta‐sis was obtained than that in the group without lymph mode metastasis (P<0 .05) .The expression of VEGF was not found to be related with histological classification (P>0 .05) .The expression of Bax in NSCLC tissue was lower than that in normal tissue ,the differences was statistically significant (P<0 .05) .The lower expression of Bax in the group of stage Ⅲ‐Ⅳ was obtained than that in the group of stage Ⅰ‐Ⅱ (P<0 .05) .The lower expression of Bax in the group with lymph mode metastasis was obtained than that in the group without lymph mode metastasis (P<0 .05) .The expression of Bax was not found to be related with histological classification (P>0 .05) .The expression of VEGF was negatively correlated with Bax in NSCLC (P<0 .05) .Conclusion The ex‐pression of VEGF played a promoting effect in the NSCLC ,and was negatively correlated with the expression of Bax protein ,and the expression of the two could provide a basis for the diagnosis and prognosis of NSCLC .

Overexpression of human ether-脿-go-go (eag) related gene (hERG) has been found in a broad range of human leukemia cell lines and primary human leukemia. The block of hERG protein might be a potential therapeutic strategy for leukemia. Gambogic acid (GA) has recently exhibited marked anti-tumor potency on solid tumors of various derivations. Here, we investigated the anti-leukemia effects of GA and its relation to the regulation of hERG in K562 leukemia cells in vitro. K562 cells were treated with various concentrations of GA (0.125-8.0 micromol/L) for 0-72 h. MTT assay was used to evaluate the inhibition effect of GA on the growth of K562 cells. Cell apoptosis was measured through both Annexin-V FITC/PI double-labeled cytometry and transmission electron microscopy. Cell cycle regulation was studied by a propidium iodide method. RT-PCR and Western blot were applied to detect the expression level of hERG in K562 cells. GA presented striking growth inhibition and apoptosis induction potency on K562 cells in vitro in a time- and dose-dependent manner. The IC(50) value of GA for 24 h was 2.637+/-0.208 micromol/L. Moreover, GA induced K562 cells arrested in G(0)/G(1) phase, accordingly, cells in S phase decreased gradually, and no obvious changes were found in G(2)/M phase cells. Under the transmission electron microscopy, apoptotic bodies containing nuclear fragments were found in GA-treated K562 cells. After treatment with GA of 2.0 micromol/L for 24 h, the percentage of apoptotic cells was increased from 4.09% to 18.47% (P<0.01). Overexpression of hERG channel was found in K562 cells, while GA could down-regulate it at both protein and mRNA levels (P<0.01). It was concluded that GA exhibited its anti-leukemia effects partially through down-regulating the expression level of hERG channel in K562 cells, suggesting that GA may be a potential agent against leukemia with a mechanism of blocking hERG channel.

In order to investigate the anti-leukemia effects of gambogic acid (GA) and its relation to the regulation of nucleoporin Nup88 in U937 cells in vitro, the inhibitory effect of GA on the growth of U937 cells was examined by using MTT assay. Apoptosis was detected by Annexin-V FITC/PI double-labeled cytometry. Cell cycle regulation was studied by propidium iodide method. Both flow cytometry (FCM) and RT-PCR were employed to assess the expression of Nup88, and the localization of Nup88 was determined by confocal microscopy. The results indicated that GA had strong inhibitory effect on cell proliferation and apoptosis induction activity in U937 cells in vitro in a time-and dose-dependent manner. The 24-h IC(50) value was (1.019+/-0.134) mg/L. Moreover, GA induced arrest of U937 cells in G(0)/G(1) phase. Over-expression of Nup88 was found in U937 cells, whereas GA could significantly down-regulate both the protein and mRNA levels of Nup88. Nup88 was diffusely distributed between nucleus and cytoplasm and was located at the cytoplasmic side of nuclear rim, and occasionally in cytoplasm. It is suggested that GA exerts its anti-leukemia effects by regulating the expression and distribution of nucleoporin Nup88. It promises to be new agent for the treatment of acute leukemia.
Antineoplastic Agents, Phytogenic/*pharmacology ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; Nuclear Pore Complex Proteins/genetics ; Nuclear Pore Complex Proteins/*metabolism ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; U937 Cells ; Xanthones/*pharmacology

OBJECTIVE:To investigate the effects and safety of rosuvastatin on blood lipid and thyroid nodules in elderly pa-tients with dyslipidemia. METHODS:70 elderly patients with dyslipidemia were selected and randomly divided into control group (33 cases) and treatment group (37 cases). Control group was treated with routine treatment as abstain from tobacco and drink, low fat diet,Aspirin enteric-coated tablets 100 mg at bed time;treatment group was additionally treated with Rosuvastatin calcium tablet 10 mg at bed time,on the basis of control group. Both groups received the treatment for consecutive 12 weeks. BMI,blood lipid and the size of thyroid nodules were compared between 2 groups before and after treatment,and the occurrence of ADR was also observed. RESULTS:There was no significant difference in BMI between 2 groups before and after treatment (P>0.05). There was no significant difference in blood lipid level and the size of thyroid nodules between 2 groups before and after treatment (P>0.05). The blood lipid level and the size of thyroid nodule of 2 groups were improved significantly after treatment,and the treatment group was significantly better than the control group,with statistical significance(P<0.05). 2 pationts of creatment suf-fered from the increase of ALT but recovered withont angtreatment. CONCLUSIONS:Rosuvastatin can significantly improve blood lipid and decrease thyroid nodules in elderly patients with dyslipidemia with good safety.

Objective To establish an animal model of heart failure with preserved ejection fraction(EF)resulting from hypertension.Methods35 male New-Zealand rabbits were randomly assigned to 2 groups:constriction was performed at the abdominal aorta 1 cm just above right renal artery in operated group(n=25),and the sham-operated animals were taken as control group(n=10).The clinical manifestations of heart failure were followed up carefully.Systolic and diastolic function,and systemic hemodynamics were investigated with echocardiography and left ventricle catheter.ResultsIn operated group,marked ventricular hypertrophy was observed 2 weeks after operation.4 weeks after operation,the clinical manifestations of heart failure presented,and IVRT and LVEDP increased,and-dp/dt max decreased.Tissue doppler image indicated that e/a ratio of annulus of mitral valve decreased(P<0.05).However,EF and +dp/dt max were preserved.ConclusionThe operated animals presented the clinical manifestation of heart failure,and diastolic function of left ventricle injured,however,ejection fraction was preserved,which corresponded with the character of heart failure with preserved ejection fraction resulting from hypertension.

Objective To study the correlation between N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac diastolic and systolic function. Methods 60 New Zealand male rabbits were randomly assigned to two groups. The abdominal aorta 1 cm just above right renal artery were constricted in operated group. The clinical manifestation of heart failure was observed, and cardiac structure and function were investigated with echocardiography. Concentration of serum NT-proBNP was determined regularly. Results The concentration of NT-proBNP was correlated with Sm（r=－0.635,P=0.000）, Em（r=－0.693,P=0.000）, E/Em（r=0.688,P=0.000）, E/Vp（r=0.707, P=0.000）, and EF（r=－0.395,P=0.001）. Conclusion Concentration of serum NT-proBNP could prognose the diastolic and long axis systolic function of left ventricle.

Adenocarcinoma ; pathology ; Humans ; Lung Neoplasms ; pathology